Mesothelin and TGF-α predict pancreatic cancer cell sensitivity to EGFR inhibitors and effective combination treatment with trametinib

Clinical trials of EGFR inhibitors in combination with gemcitabine for the treatment of pancreatic ductal adenocarcinoma (PDAC) have generated mixed results partially due to the poorly defined effectiveness of EGFR inhibitors in PDAC. Here, we studied a panel of PDAC cell lines to compare the IC50s...

Descripción completa

Detalles Bibliográficos
Autores principales: Poteet, Ethan, Liu, Dongliang, Liang, Zhengdong, Van Buren, George, Chen, Changyi, Yao, Qizhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438513/
https://www.ncbi.nlm.nih.gov/pubmed/30921351
http://dx.doi.org/10.1371/journal.pone.0213294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438513/
https://www.ncbi.nlm.nih.gov/pubmed/30921351
http://dx.doi.org/10.1371/journal.pone.0213294

Ejemplares similares